New light- and drug-controlled tools to calm overactive brain circuits
New classes of optogenetic and chemogenetic tools with a feedback control
Researchers are creating new light- and drug-activated tools to quickly and safely quiet overactive brain circuits in people with epilepsy, anxiety, or related conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11062750 on NIH RePORTER |
What this research studies
You should know the team is engineering next-generation optogenetic (light-controlled) and chemogenetic (drug-controlled) biological tools that include built-in feedback so they respond only when brain activity becomes abnormal. The project aims to combine fast on/off control with the ability to provide longer-lasting suppression without tissue heating from prolonged light exposure. Work will use laboratory models to test timing, dose, and modular designs that target specific neuronal pathways. The ultimate goal is minimally invasive approaches that can be tuned for different neurological conditions.
Who could benefit from this research
Good fit: Ideal candidates for future clinical translation would be people with epilepsy or severe anxiety whose symptoms do not respond well to current medications and who are open to novel neuromodulation approaches.
Not a fit: People with mild, well-controlled symptoms or disorders not driven by abnormal neuronal firing patterns may not benefit from these approaches.
Why it matters
Potential benefit: If successful, this could enable therapies that stop seizures or extreme anxiety episodes quickly while allowing longer-term control with fewer side effects.
How similar studies have performed: Related optogenetic and chemogenetic approaches have shown clear effects in animal models, but human-use versions remain largely experimental and unproven.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wang, Wenjing — University of Michigan at Ann Arbor
- Study coordinator: Wang, Wenjing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.